Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROPACE, INC.

(NPCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NeuroPace : Earnings Flash (NPCE) NEUROPACE Reports Q2 Revenue $12.6M, vs. Street Est of $11.3M

08/12/2021 | 04:05pm EDT


© MT Newswires 2021
All news about NEUROPACE, INC.
10/20NEUROPACE : to Report Third Quarter 2021 Financial Results on November 10, 2021
GL
10/20NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021
GL
10/19NEUROPACE INC : Change in Directors or Principal Officers (form 8-K)
AQ
10/19NEUROPACE : Announces Addition of Lisa Andrade to the Board
AQ
10/19Neuropace, Inc. Announces Addition of Lisa Andrade to the Board
CI
10/19Certain Common Stock of NeuroPace, Inc. are subject to a Lock-Up Agreement Ending on 19..
CI
10/19Certain Stock Options of NeuroPace, Inc. are subject to a Lock-Up Agreement Ending on 1..
CI
09/20NEUROPACE, INC.(NASDAQGM : NPCE) added to S&P Global BMI Index
CI
09/09NEUROPACE INC : Regulation FD Disclosure (form 8-K)
AQ
08/23NEUROPACE : to Participate in Upcoming Conferences
AQ
More news
Analyst Recommendations on NEUROPACE, INC.
More recommendations
Financials (USD)
Sales 2021 47,0 M - -
Net income 2021 -32,9 M - -
Net Debt 2021 1,09 M - -
P/E ratio 2021 -9,37x
Yield 2021 -
Capitalization 376 M 376 M -
EV / Sales 2021 8,03x
EV / Sales 2022 6,62x
Nbr of Employees 159
Free-Float 61,5%
Chart NEUROPACE, INC.
Duration : Period :
NeuroPace, Inc. Technical Analysis Chart | NPCE | US6412881053 | MarketScreener
Technical analysis trends NEUROPACE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 15,49 $
Average target price 27,00 $
Spread / Average Target 74,3%
EPS Revisions
Managers and Directors
Michael Favet President, Chief Executive Officer & Director
Rebecca L. Kuhn CFO, Vice President-Finance & Administration
Frank M. Fischer Chairman
Martha J. Morrell Chief Medical Officer
Cairn Seale Vice President-Clinical & Research
Sector and Competitors
1st jan.Capi. (M$)
NEUROPACE, INC.0.00%376
THERMO FISHER SCIENTIFIC27.12%238 254
DANAHER CORPORATION38.87%224 750
INTUITIVE SURGICAL, INC.24.61%121 299
SIEMENS HEALTHINEERS AG39.83%76 668
EDWARDS LIFESCIENCES CORPORATION26.06%72 057